drugset / Trial / NCT03950609
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
Phase 2
Active not recruiting
36 enrolled
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well lenvatinib and everolimus work in treating patients with carcinoid tumors that have spread to other places in the body (advanced) and cannot be removed by surgery (unresectable). Lenvatinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2019-07-30
- Primary completion
- 2028-03-30
- Completion
- 2028-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | — | Oral |
| Subject | Lenvatinib | Small molecule | — | Oral |